1. Home
  2. AHG vs NUVB Comparison

AHG vs NUVB Comparison

Compare AHG & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHG
  • NUVB
  • Stock Information
  • Founded
  • AHG 2013
  • NUVB 2018
  • Country
  • AHG China
  • NUVB United States
  • Employees
  • AHG N/A
  • NUVB N/A
  • Industry
  • AHG Business Services
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • AHG Consumer Discretionary
  • NUVB Health Care
  • Exchange
  • AHG Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • AHG 765.9M
  • NUVB 837.0M
  • IPO Year
  • AHG N/A
  • NUVB N/A
  • Fundamental
  • Price
  • AHG $1.70
  • NUVB $2.35
  • Analyst Decision
  • AHG
  • NUVB Strong Buy
  • Analyst Count
  • AHG 0
  • NUVB 6
  • Target Price
  • AHG N/A
  • NUVB $7.83
  • AVG Volume (30 Days)
  • AHG 94.8K
  • NUVB 5.0M
  • Earning Date
  • AHG 08-12-2025
  • NUVB 08-07-2025
  • Dividend Yield
  • AHG N/A
  • NUVB N/A
  • EPS Growth
  • AHG N/A
  • NUVB N/A
  • EPS
  • AHG N/A
  • NUVB N/A
  • Revenue
  • AHG $8,454,946.00
  • NUVB $10,957,000.00
  • Revenue This Year
  • AHG N/A
  • NUVB $98.78
  • Revenue Next Year
  • AHG N/A
  • NUVB $489.71
  • P/E Ratio
  • AHG N/A
  • NUVB N/A
  • Revenue Growth
  • AHG 281.19
  • NUVB N/A
  • 52 Week Low
  • AHG $0.74
  • NUVB $1.54
  • 52 Week High
  • AHG $2.35
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • AHG 51.61
  • NUVB 53.31
  • Support Level
  • AHG $1.56
  • NUVB $2.46
  • Resistance Level
  • AHG $2.10
  • NUVB $2.76
  • Average True Range (ATR)
  • AHG 0.25
  • NUVB 0.16
  • MACD
  • AHG -0.02
  • NUVB 0.01
  • Stochastic Oscillator
  • AHG 27.75
  • NUVB 41.43

About AHG Akso Health Group ADS

Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: